Brief: Immunovant Reports Cash Balance Of About $433 Mln As Of December 31

Immunovant

03/02/2023 12:49

Feb 3 (Reuters) - Immunovant Inc  IMVT.O :
    * IMMUNOVANT REPORTS FINANCIAL RESULTS AND RECENT BUSINESS
UPDATES
FOR THE QUARTER ENDED DECEMBER 31, 2022
    * IMMUNOVANT INC - CASH BALANCE OF ABOUT $433 MILLION AS OF
DECEMBER 31, 2022
    * IMMUNOVANT INC - A PHASE 1 CLINICAL TRIAL OF IMVT-1402 IS
ON
TRACK TO BE INITIATED IN EARLY CALENDAR YEAR 2023
    * IMMUNOVANT INC - PHASE 3 CLINICAL TRIAL OF BATOCLIMAB IN
MYASTHENIA GRAVIS (MG) IS ONGOING
    * IMMUNOVANT INC - PHASE 3 CLINICAL TRIAL OF BATOCLIMAB IN
THYROID
EYE DISEASE (TED) WERE INITIATED, AS EXPECTED
    * IMMUNOVANT INC - PHASE 2B CLINICAL TRIAL IN CHRONIC
INFLAMMATORY
DEMYELINATING POLYNEUROPATHY (CIDP) WERE INITIATED, AS EXPECTED
    * IMMUNOVANT INC - QTRLY NET LOSS PER COMMON SHARE $0.49

Source text for Eikon:  ID:nGNX4TFyT7 
Further company coverage:  IMVT.O 
 ((Reuters.Briefs@thomsonreuters.com;))